News
12-29-2010, 10:30 PM
ZIOPHARM Oncology, Inc., announced today that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers.
More... (http://www.news-medical.net/news/20101229/Dosing-initiated-in-combination-Phase-I-study-of-palifosfamide-with-etoposide-and-cisplatincarboplatin-in-SCLC.aspx)
More... (http://www.news-medical.net/news/20101229/Dosing-initiated-in-combination-Phase-I-study-of-palifosfamide-with-etoposide-and-cisplatincarboplatin-in-SCLC.aspx)